Nexalin Technology, Inc. — Form 8-K Summary
Reporting date: September 28, 2026 (earliest event reported); filed/signed October 1, 2026. The filing reports a material distribution agreement and related press release, not periodic financial results.
Business context and agreement
On September 28, 2026, Nexalin entered into a Distribution Agreement effective September 22, 2026, with the founders of INOVANEXA MEDICAL TECHNOLOGIES S.A., a Brazilian corporation in formation. The distributor receives exclusive rights to import, distribute, commercialize, promote, and sell Nexalin Sync devices and related products in Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador, and Venezuela.
The initial term is ten years, with automatic successive ten-year renewals subject to compliance, including revenue performance requirements. Nexalin retains ownership of product intellectual property and exclusively supplies the encrypted circuit boards needed for the devices. The distributor bears importation, regulatory, marketing, and local manufacturing costs.
Financial and commercial terms
- The agreement describes an initial 100-device commercialization program with tiered per-device pricing; the filing does not provide a clear price or total contract value.
- The distributor is required to place an initial binding order for five devices following signature, intended for a Brazilian clinical pilot targeted to launch within 90 days, and order five additional devices within twelve months of the pilot. No other product purchases are required except as affected by performance requirements.
- Minimum aggregate revenues to Nexalin are required during the first 30 months after pilot launch, followed by minimum annual revenues. The specific thresholds are not stated in the filing’s summary of the agreement.
- For qualifying private-sector transactions involving devices manufactured or assembled in Brazil during the initial program, the parties may agree to alternative structures, including equal sharing of gross profit.
- After purchase of the first 30 devices, the distributor must establish a Brazilian manufacturing facility at its own expense under a separate agreement to be negotiated. Nexalin would receive fixed per-device compensation for locally manufactured devices placed in the marketplace and a per-unit royalty on locally manufactured disposables.
The 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial-statement metrics, and no comparable prior-period results.
Implementation, outlook, and risks
- An existing Brazilian regulatory holder is expected to retain the ANVISA approvals needed to import and sell the products during a transition period of up to 30 months. Transfer of approvals to the distributor depends on performance; the distributor would then be responsible for regulatory approvals in the territory.
- Exclusivity may be revoked, and the agreement may be terminated in specified circumstances, if performance requirements are not met. Customary termination provisions include uncured payment defaults, uncured material breach, insolvency, and change of control.
- The company identifies as forward-looking matters the expected benefits and performance of the agreement, orders, pilot timing, local manufacturing, performance against revenue requirements, and regulatory approvals. Results depend on execution and regulatory outcomes and are subject to risks described in the company’s 2025 Form 10-K and subsequent SEC filings.
- The agreement includes customary provisions addressing payment, delivery, warranties, product liability, confidentiality, anti-corruption compliance, and force majeure. Certain exhibit schedules and confidential information were omitted.
Important facts for investors to verify
- Whether the distributor places and pays for the required initial five-device order and the subsequent five-device order.
- The pilot’s actual launch date, deployment, and commercial progress.
- The agreement’s revenue thresholds and whether they are met, including implications for exclusivity and renewal.
- Regulatory approval status and any transfer of ANVISA approvals to the distributor.
- Whether the parties execute the separate manufacturing and licensing agreement, and the resulting economics and facility timeline.
- Full agreement terms, including pricing and any omitted or redacted provisions, in Exhibit 10.1.